Cisplatin combined with high-intensity focused ultrasound inhibits endometrial cancer progression by inducing pyroptosis

<p>Cisplatin-based chemotherapy is limited by toxicity and resistance.High-intensity focused ultrasound (HIFU) is a noninvasive ablation technique with potential to enhance chemotherapy efficacy.</p> <p>To investigate the anti-tumor effects and mechanisms of cisplatin combined with HIFU in endometrial cancer.</p> <p>Safe cisplatin concentrations and HIFU parameters were screened in HEEpiC-SV40 cells. Proliferation, apoptosis, migration, and invasion of Ishikawa cells were assessed using CCK-8, EdU, colony formation, TUNEL, wound healing, and Transwell assays.

Pyroptosis-related markers and PI3K/AKT pathway activity were evaluated by Western blot, qRT-PCR, and ELISA. Therapeutic efficacy was further examined in a nude mouse xenograft model.</p> <p>Cisplatin (5 μg/mL) combined with HIFU (1 MHz, 160 J) was identified as the optimal treatment condition. The combination significantly inhibited Ishikawa cell proliferation, migration, and invasion while promoting pyroptosis.